Marsh vs. Health In Tech: A Comprehensive Financial Comparison

Financial services companies Marsh & McLennan Companies, Inc. and Health In Tech, Inc. have recently been the focus of a detailed financial comparison to determine which business stands out in terms of valuation, profitability, risk, and institutional ownership.

Comparative Financial Analysis

In evaluating the financial health of these two companies, key metrics such as gross revenue, earnings per share, and price-to-earnings ratios provide valuable insights. As of the latest reports, Marsh has achieved a gross revenue of $26.98 billion with a net income of $4.16 billion, while Health In Tech reported substantially lower figures, with gross revenue of $30.72 million and net income of $1.71 million. This data highlights Marsh’s position as a significantly larger player in the market.

When considering their valuations, Marsh trades at a price-to-earnings ratio of 20.86, which is notably lower than Health In Tech’s ratio of 36.00. This suggests that Marsh may be a more affordable investment, offering better value for shareholders at present.

Ownership and Analyst Perspectives

Ownership structure is another critical factor in assessing these companies. Approximately 88.0% of Marsh’s shares are held by institutional investors, indicating strong confidence from large financial entities in the company’s long-term performance. In contrast, Health In Tech has 77.7% of its shares held by company insiders, a figure that reflects a different kind of confidence in its potential.

Analyst ratings provide further clarity on market sentiment. According to data from MarketBeat.com, Marsh has received no sell ratings, six hold ratings, and eleven buy ratings, culminating in a rating score of 2.38. Health In Tech, while receiving fewer ratings, boasts a slightly better score of 2.50 with one hold and no sell ratings. Current consensus price targets suggest a potential upside of 17.94% for Marsh, translating to a target of $207.38, whereas Health In Tech’s potential upside stands at an impressive 131.48%, with a target of $2.50.

In terms of volatility, Marsh has a beta of 0.75, indicating it is less volatile than the S&P 500 by 25%. Conversely, Health In Tech’s beta of 8.53 indicates a striking 753% increase in volatility compared to the S&P 500, which may present higher risks for investors.

Profitability metrics also reveal a stark contrast. Marsh has a net margin of 15.42%, a return on equity of 31.60%, and a return on assets of 8.26%. Health In Tech, on the other hand, does not currently report comparable figures in these categories, making direct profitability comparisons challenging.

In summary, Marsh surpasses Health In Tech in nine out of fourteen key factors evaluated, reinforcing its position as a more established entity in the financial services landscape.

About Marsh & McLennan Companies, Inc.
Founded in 1871 and headquartered in New York, New York, Marsh & McLennan provides a range of professional services in risk, strategy, and people management. The company operates through two main segments—Risk and Insurance Services, and Consulting—serving a diverse clientele including businesses, public entities, and private clients.

About Health In Tech, Inc.
Established in 2014 by Tim Johnson, Health In Tech is based in Stuart, Florida. The company specializes in insurance technology platforms, offering various services aimed at improving processes within the healthcare industry.